Cargando…
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
There has been substantial evolution in the treatment of metastatic renal cell carcinoma with notable changes in the first-line setting. Currently, doublet combination therapy with either two immune checkpoint inhibitors or a combination of an immune checkpoint and tyrosine kinase inhibitor is consi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114990/ https://www.ncbi.nlm.nih.gov/pubmed/37062953 http://dx.doi.org/10.1080/21645515.2023.2193528 |